Reports Q4 revenue $330.7M, consensus $296.6M. "Our 2022 performance reflects the transition the company is undergoing and, together with our 2023 forecast, stands as a baseline from which we will grow post-pandemic," said Robert G. Kramer, president and CEO of Emergent BioSolutions. "Moving forward, our strategy will continue to put patients and customers first and support governments and their public health preparedness and response capabilities while returning Emergent to sustainable long-term growth and profitability."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on EBS:
- Emergent BioSolutions Reports Financial Results for Fourth Quarter 2022
- Emergent BioSolutions Reports FDA Advisory Committees’ Unanimous Vote in Favor of NARCAN® (naloxone HCI) Nasal Spray for Over-the-Counter Use
- Emergent announces FDA advisory committees vote in favor of OTC Narcan
- FDA Joint Committee Meeting
- Emergent Surges after Selling its Travel Health Business for $380 Million